Xigris licence withdrawn

Xigris was indicated for the treatment of severe sepsis with multiple organ failure | SCIENCE PHOTO LIBRARY
Xigris was indicated for the treatment of severe sepsis with multiple organ failure | SCIENCE PHOTO LIBRARY

Xigris (activated drotrecogin alfa) has been withdrawn by Lilly after it failed to show a survival benefit in a clinical trial in patients with septic shock.

Results from the PROWESS-SHOCK study showed the overall 28-day mortality was 26.4% in drotrecogin-alfa-treated patients (n=846) compared with 24.2% in patients given placebo (n=834; p=0.31). No new safety findings were observed.

Drotrecogin alfa must not be initiated in new patients and should be discontinued in patients currently receiving treatment.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases